(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
A Past filled with Old Civilizations: The World's Most established Societies - 2There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- 3Vote In favor of Your Favored IT Administration
- 4They grew up with 'almond moms.' Now, they dread going home for the holidays.
- 5As Western heat wave ends, scientists try to make sense of its length and intensity
- Best Wellness Tracker Keep You On target
- NASA unveils close-up pictures of the comet popping by from another star
- 6 Financial plan 3D Printers with the Best Worth
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- At least 36 dead in major fire in Hong Kong residential blocks
- The top astronomical discoveries of 2025
- Vote In favor of Your Favored Video Conferencing Administration
- Holiday season sees uptick in norovirus cases, according to CDC
- What were the little white pills found in Tiger Woods's pocket at the scene of his crash? What to know about hydrocodone.
